AVEO stock: buy or sell?
September 20th, 2019
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF\u002Fc-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study.
Should I buy AVEO stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with AVEO stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is AVEO Pharmaceuticals stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 11 ratings published for AVEO stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-10||Piper Jaffray Companies||n/a||Overweight|
|2019-1-31||Piper Jaffray Companies||n/a||Overweight|
AVEO stock analysis
AVEO Pharmaceuticals ended today at $0.98 and rose a remarkable 2.08%.
AVEO Pharmaceuticals shares rose 2.08% to $0.98 today. From a daily perspective, AVEO is in a short term uptrend after plotting its last bottom ($0.85, on Sep/13) higher than the previous bottom, and its last top ($1.12, on Tuesday) also over the previous top. Now trading in between its last bottom and last top AVEO might consolidate in a plain range, waiting to break out over $1.12 or down under $0.85.
After boosting an astounding 27.66% in a week last week, AVEO Pharmaceuticals closed this week at $0.98 and soared a cool 4.26%. Early August AVEO plummed a bloodcurdling -6.15% in just one week.
Since last week when AVEO stock price broke up the SMA40w line, it gained $0.30 (44.12%).
AVEO stock price history
AVEO IPO was on March 12th, 2010 at $8.25 per share1. Since then, AVEO stock lost a -88.10%, with a yearly average of -9.80%.
1: Adjusted price after possible price splits or reverse-splits.
AVEO stock historical price chart
AVEO stock reached 52-week highs on September at $3.59, and all-time highs 2011-07-06 with a price of 21.55.
AVEO stock price target is $2.80How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 10 price targets for AVEO stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-10||Piper Jaffray Companies||Raises Target||$3.00||$4.00||33.3%|
|2019-1-31||Piper Jaffray Companies||Reiterates||$5.00||$3.00||-40%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAVEO let down analysts on March when it published an Earnings per Share (EPS) of $-0.03 when the market consensus was $-0.06.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, AVEO Pharmaceuticals annual turnover collapsed a spooky -28.63% to $5.41 million USD from $7.58 marked in 2017. On the other hand, its earnings margin (compared to sales) rocketed to -98.52%, that is $-5.33 million.
|2013||$1.29 M||-||$-107.03 M-8296.9%||-|
|2014||$18 M||1,304.88%||$-52.74 M-291.0%||-50.73%|
|2015||$19 M||4.97%||$-15.00 M-78.9%||-71.56%|
|2016||$2.52 M||-86.78%||$-26.89 M-1069.1%||79.23%|
|2017||$7.58 M||201.35%||$-65.03 M-858.0%||141.85%|
|2018||$5.41 M||-28.63%||$-5.33 M-98.5%||-91.80%|
Quarterly financial resultsAVEO Pharmaceuticals reported $1.48 million in revenues for 2018-Q4, a -39.89% less compared to previous quarter. Reported quarter earnings marked $21.82 M with a profit margin of 1,471.21%. Profit margin skyrocketed a 2,369.59% compared to previous quarter when profit margin was -898.38%. When comparing turnover to same quarter last year, AVEO sales marked an amazing gain and climbed a 1,708.54%.
|2017-Q1||$2.53 M||-||$-8.84 M-349.4%||-|
|2017-Q2||$0.35 M||-86.13%||$-33.29 M-9484.3%||276.58%|
|2017-Q3||$4.61 M||1,214.53%||$-26.40 M-572.1%||-20.71%|
|2017-Q4||$0.08 M||-98.22%||$3.50 M4267.1%||-113.26%|
|2018-Q1||$1.03 M||1,151.22%||$-8.99 M-876.0%||-356.87%|
|2018-Q2||$0.43 M||-57.80%||$4.00 M924.7%||-144.55%|
|2018-Q3||$2.47 M||469.75%||$-22.16 M-898.4%||-653.52%|
|2018-Q4||$1.48 M||-39.89%||$21.82 M1471.2%||-198.44%|
AVEO ownershipWhen you are planning to invest in shares of a company, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For AVEO Pharmaceuticals, 0.28% of all outstanding shares are owned by its staff.
In case of AVEO stock, 32.51% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AVEO stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to AVEO Pharmaceuticals:
|Market cap||$157.5 M||$118.1 B||$964.5 M||$44.0 B||$82.9 B|
|Total shares||160.7 M||599.7 M||120.3 M||184.5 M||1,640.0 M|
|Float shares||134.8 M||598.3 M||93.2 M||184.0 M||1,630.0 M|
|- Institutional holdings (%)||32.5%||81.9%||81.2%||93.4%||75.0%|
|- Insider holdings (%)||0.3%||0.2%||1.7%||0.5%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$0.95 - $1.01|
|Average true range||$0.09|
|50d mov avg||$0.73|
|100d mov avg||$0.74|
|200d mov avg||$0.96|
AVEO performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For AVEO Pharmaceuticals, the comparison is made against Amgen, ArQule, Biogen, Bristol-Myers Squibb, Eli Lilly and, Merrimack Pharmaceuticals and Regeneron Pharmaceuticals.
|LLYEli Lilly and||1.14%||-8.44%||11.63%|